REMAP-CAP is a randomised, multi-factorial, adaptative platform trial for community-acquired pneumonia which was later adapted to the COVID-19 pandemics.

Primary objective: To identify the effect of a range of interventions to improve outcome as defined by 21-day ICU free days.

Type of study: Interventional, RCT, Phase 3

Treatment tested: Multiple

Countries: Multiple

Sample size: Adaptative trial therefore no prespecified sample size

Study participants:  Suspected or proven COVID-19 infection (for the COVID-19 Domains)

Study status: Ongoing

Study documents

• Protocol Summary 
• REMAP-CAP Core Protocol 
• Pandemic Appendix to the Core Protocol 
• REMAP-COVID Core Protocol 
• Operational characteristics of the Pandemic Appendix to the Core Protocol

Investigators (study chairs)

• Steve Webb, Prof., Monash University
• Colin McArthur, Dr, Medical Research Institute of New Zealand
• Marc Bonten, Prof., UMC Utrecht
• Lennie Derde, MD, UMC Utrecht
• Marshall Marshall, Prof., Unity Health Toronto
• Angus Derek, Prof., University of Pittsburgh Medical Center

More information

• Study ID: NCT02735707 
• Trial registry
• Study website
• Publication: JAMA, September 2020

Last updated: September 2020

Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.